Toxins as medicine

Newly formed biopharmaceutical company Syntaxin

Jul 06, 2006|1 min read

Randall C Willis

Listen with Speechify

0:00

5:00

SALISBURY, U.K.—Newly formed biopharmaceutical company Syntaxin announced it has been awarded a collaborative R&D grant from the UK Department for Trade and Industry valued at £1.2 million. Syntaxin will work with scientists at the Advanced Centre for Biochemical Engineering (ABCE) at University College London and the U.K. Health Protection Agency (HPA) to develop new methods for processing complex proteins to treat chronic diseases.

"This award provides us with an excellent opportunity to work with two world-class institutions to develop new and improved manufacturing processes that we will be able to apply to our development programmes," says Dr. Keith Foster, Syntaxin CSO. "The knowledge that we will generate through this programme will accelerate our ability to bring important new medicines for chronic diseases to the market."

Under the deal, Syntaxin will design novel recombinant proteins as candidate biopharmaceuticals, while ABCE will optimize the bioprocessing and HPA will work on system scale-up for manufacturing.